A Clinical Trial Evaluating TQF3250 Capsules in Patients With Type 2 Diabetes Mellitus and Overweight/Obesity
Condition: Type 2 Diabetes Mellitus Combined With Overweight or Obesity · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
About this study
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b clinical study designed to evaluate the safety, tolerability, pharmacokinetic profiles and preliminary efficacy of multiple oral doses of TQF3250 capsules in trial subjects with type 2 diabetes mellitus complicated with overweight or obesity. A total of 72 eligible subjects are planned to be enrolled in this study. Six treatment dose groups are established, including 4 mg, 8 mg, 12 mg, 24 mg, 32 mg and 40 mg, with a dose-escalation titration design. Each dose group will consist of 12 subjects. Eligible screened subjects will be randomized at a ratio of 10:2 (10 subjects receiving investigational drug and 2 subjects receiving placebo) to receive treatment with either TQF3250 capsules or matching placebo.
This description comes directly from the study's public registry record.
Talk to the study team
Dalong Zhu, Doctor · 13805150781 · zhudalong@nju.edu.cn
Juan Li, Doctor · 15951989771 · Juanli2003@163.com
Always discuss trial participation with your own doctor first.
Locations (12)
| Fuzhou University Affiliated Provincial Hospital | Fuzhou, Fujian, China | — |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, Guangdong, China | — |
| Hebei Petro China Central Hosptial | Langfang, Hebei, China | — |
| Luoyang First People's Hospital | Luoyang, Henan, China | — |
| Zhongnan Hospital of Wuhan University | Wuhan, Hubei, China | — |
| Yichang Central People's Hospital | Yichang, Hubei, China | — |
| The Third Hospital of Changsha | Changsha, Hunan, China | — |
| Nanjing Drum Tower Hospital | Nanjing, Jiangsu, China | — |
| Central Hospital Affiliated to Shandong First Medical University | Jinan, Shandong, China | — |
| Shanghai Tenth People's Hospital | Shanghai, Shanghai Municipality, China | — |
| Affiliated Hospital of Southwest Medical University | Luzhou, Sichuan, China | — |
| The First People's Hospital of Xiaoshan Hangzhou | Hangzhou, Zhejiang, China | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07747857